Beurs.nl monitor iconMarkt Monitor
  • AEX +0,32 819,56 +0,04%
  • DE40 0,00 20.374,10 0,00%
  • US500^ 0,00 5.358,26 0,00%
  • US30^ 0,00 40.214,00 0,00%
  • EUR/USD 0,00 1,1356 -0,03%
  • WTI 0,00 61,48 0,00%
  • Gold spot -14,18 3.223,28 -0,44%

WAVE LIFE SCIENCES LTD (2023) WVE

5 Posts
| Omlaag ↓
  1. forum rang 4 Piddy 10 april 2023 19:44
    info 01/2023

    The BPs are making there moves into the RNA modality.

    GSK:
    Wave Life Sciences has picked up another deal with a major pharma company.
    The Massachusetts-based biotech on Tuesday announced it has entered a strategic collaboration with GSK to advance oligonucleotide therapeutics. This includes moving along Wave’s RNA editing program that targets alpha-1 antitrypsin deficiency, dubbed WVE-006, which affects both the lungs and liver with limited treatment options.
    The deal will have a four-year research term at the beginning. It will bring together GSK’s experience in human genetics, along with its wider development and commercial abilities, with Wave’s drug discovery and development platform, called PRISM. The deal also has two elements, first a discovery collaboration, allowing GSK to potentially advance up to eight programs and Wave to advance up to three. GSK also receives the exclusive global license for WVE-006.
    Wave will get an upfront payment of $170 million, split into a $50 million equity investment and $120 million in cash. The WVE-006 program can see Wave receive up to $225 million in development and launch payments and $300 million in sales milestones.
    Once RNA editing gains POC (and I suspect GSK and Lilly already have positive clues to that effect) these stocks will pop.

    Wave continues to lead the genetic medicines field in advancing therapeutic RNA editing toward the clinic with our WVE-006 AIMer program and we expect to submit clinical trial applications for our first-in-human study in 2023. WVE-006 is distinct from other approaches in development for AATD, as it offers the opportunity to treat the root genetic cause of the disease and restore functional, wild-type protein that remains under physiological regulation. This would be a holistic solution and applicable to those with lung disease, liver disease, or both,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “Additionally, the opportunity for AIMers is much broader than restoring or correcting protein function in genetic diseases, as we demonstrated today with our preclinical data supporting the use of AIMers to modulate protein-protein interactions and upregulate gene expression. RNA editing is emerging as a distinct class of therapeutics with potential to address disease biology in novel and innovative ways and reach patients suffering from an array of diseases, including neurological disorders, as well as renal, cardiometabolic, or immunologic diseases. We are proud to be pioneers in this new area of genetic medicine and to have a best-in-class RNA editing capability with our AIMers.”
    ir.wavelifesciences.com/news-releases...
  2. forum rang 4 Piddy 10 april 2023 19:47
    Eerste deftige aankoop geplaatst
    GAK $ 4,58

    Vanaf $5 vragen we wel een eigen draadje aan.
  3. forum rang 4 Piddy 10 april 2023 20:27
    HC Wainwright Adjusts First Wave BioPharma Price Target to $14 From $18, Maintains Buy Rating | MarketScreener
5 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.163
AB InBev 2 5.544
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.507
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.931
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.892
Aedifica 3 927
Aegon 3.258 323.213
AFC Ajax 538 7.093
Affimed NV 2 6.306
ageas 5.844 109.909
Agfa-Gevaert 14 2.074
Ahold 3.538 74.363
Air France - KLM 1.025 35.331
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.072
Alfen 16 25.503
Allfunds Group 4 1.525
Almunda Professionals (vh Novisource) 651 4.252
Alpha Pro Tech 1 17
Alphabet Inc. 1 427
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.271
AMG 972 134.761
AMS 3 73
Amsterdam Commodities 305 6.757
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.106
Apollo Alternative Assets 1 17
Apple 5 387
Arcadis 252 8.808
Arcelor Mittal 2.035 321.097
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.380
Aroundtown SA 1 221
Arrowhead Research 5 9.759
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.700
ASML 1.767 112.340
ASR Nederland 21 4.522
ATAI Life Sciences 1 7
Atenor Group 1 523
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.351
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.463